株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ファーマコビジランスおよび関連動向:業界および市場分析

Pharmacovigilance and Related Developments: Industry and Market Analysis 2014-2024

発行 Visiongain Ltd 商品コード 224395
出版日 ページ情報 英文 146 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=147.80円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
ファーマコビジランスおよび関連動向:業界および市場分析 Pharmacovigilance and Related Developments: Industry and Market Analysis 2014-2024
出版日: 2014年04月10日 ページ情報: 英文 146 Pages
概要

世界のファーマコビジランス市場は2018年に106億米ドルに達すると予測されており、2024年までさらに拡大を続ける見込みです。

当レポートでは、ファーマコビジランス市場の現状と2024年までの収益、地域別動向、参入企業のプロファイルなどをまとめ、概略下記の構成で取り上げております。

第1章 エグゼクティブサマリー

第2章 ファーマコビジランスのイントロダクション

  • 薬剤有害反応
  • 事象
  • 安全性信号とその意味、特定の仕方
  • ファーマコビジランスの歴史的展望
  • 治験における薬剤安全性モニタリング
  • 第4相:市販後調査
  • 医薬品業界におけるファーマコビジランス
  • 主要企業の実態

第3章 ファーマコビジランス:世界市場

  • WHOの国際薬剤モニタリングプログラム
  • 研究開発におけるファーマコビジランス
  • 世界市場予測
  • 促進因子と阻害因子

第4章 主な国と地域

  • 世界のファーマコビジランス市場の地域別内訳
  • 世界のファーマコビジランス市場:地域別予測
  • 米国市場
  • 欧州市場
  • ドイツ市場
  • フランス市場
  • 英国市場
  • イタリア市場
  • スペイン市場
  • 日本市場
  • BRIC諸国市場
  • 中国市場
  • ブラジル市場
  • ロシア市場
  • インド市場
  • 韓国市場

第5章 主要なファーマコビジランス企業

  • ビジネスプロセスアウトソーシング企業
  • 研究開発受託機関(CRO)
  • ソフトウェアプロバイダー
  • その他のアウトソーシング企業
  • その他のファーマコビジランスサービスプロバイダー

第6章 ファーマコビジランス市場の定性的分析

第7章 調査インタビュー

第8章 結論

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Post-marketing surveillance for medicines - discover trends, outlooks, and revenues.

Where are pharmacovigilance and related needs heading? For those pharmaceutical testing studies you get new analysis, also exploring sales predictions. You unlock that medical industry. And you assess its results, trends, technologies, prospects, and opportunities.

Visiongain's updated report forecasts those revenues to 2024 at overall world market, regional, and national level. There stay ahead in data, benefiting your influence. And hear about gains for patients, doctors, healthcare providers, and companies.

Read on, then, to explore assessments of drugs in use, also finding those services' future commercial value.

Analyses exclusive to that study, discussing the most important needs and potentials.

Demand rises for those testing, data storage, and monitoring operations. There our study benefits your plans, decisions, and authority by interpreting medical needs, regulations, and companies' efforts. Save time and effort.

And you see what's happening in surveillance of pharmaceuticals, assessing likely challenges, events, and gains. In particular discover prospects for phase IV clinical trials, contract research organisations (CROs), and pharmaceutical companies.

And in those analyses you get data found nowhere else. Our forecasting system goes to the core of sales potentials in those drug safety assessments, showing revenue predictions.

Our report gives 36 tables, 35 charts, and interviews with three companies. There you discover historical results, growth rates, market shares, discussions, and forecasts.

And the following sections show how our new investigation helps you stay ahead.

National markets - what outlooks for service demand and provision?

What's the commercial potential of post-marketing studies for medicines? For those testing activities our work forecasts overall world spending to 2024.

Our report also gives you individual forecasts to 2024 for 12 national markets:

  • United States (US)
  • Japan
  • Germany, France, UK, Italy, and Spain (EU5), also with EU regional prediction
  • Brazil, Russia, India, and China (BRIC nations), and South Korea.

Stay ahead, then, for information. There you find regions and countries with highest demands, spending, and potential sales growth. Explore progress, needs and opportunities.

Also what events, challenges, and advances in technology affect that industry and market? Our work shows you, discussing progress, policies, and trends influencing that pharma field.

Market forces, events, and issues - developments influencing pharmacovigilance.

Find what's happening. Our new report explains issues, processes, and events affecting that industry and market from 2014, including these:

  • Reporting systems for adverse drug reactions (ADRs) - their present and future, including data on reported and recorded events by year and region
  • Drug approval moving towards post-marketing studies, inc. advances in therapies
  • Safety monitoring using reporting from social media - explore possibilities in big data
  • Improvements in data collection and communication leading to more-flexible drug approval processes - changing routes of marketing authorisation
  • Strengths and weaknesses of procedures and practice in 2014, and how pharma regulatory affairs can progress there to 2024.

And it discusses these trends and influences, among others:

  • Policies of national and international bodies, and regulators' roles in present and future pharmacovigilance programmes
  • Companies in business process outsourcing (BPO), software providers, regulatory consultants, and contract research organisation (CROs)
  • Prediction of overall pharma R&D spending and its effects on that drug monitoring
  • Collaboration between the FDA and EMA, and application of pharmacogenomics and biomarkers
  • Use of electronic health record (EHR) systems - a live model for drug safety, applying information systems.

There you explore political, economic, social, and technological questions. See too how post-approval R&D lets companies benefit patients. And find what helps and what hinders players in that industry, affecting its results.

So you hear what progress, trends and prospects mean. And you assess what the future holds.

Companies and 2018 market value - find commercial potential

What happens next? Our study predicts that overall world market will reach $10.6bn in 2018, with further expansion to 2024.

Also, from 2014, outsourcing of those operations will increase. There pharmaceutical clients, contract research organisations (CROs), and other participants will benefit. See how, discovering potentials.

You examine companies, including these:

  • Pfizer
  • Johnson & Johnson
  • GlaxoSmithKline (GSK)
  • Sanofi
  • Novartis
  • AstraZeneca
  • Eli Lilly.

And also these specialist firms:

  • Quintiles
  • Covance
  • Parexel
  • Accenture
  • Cognizant Technology Solutions
  • Infosys
  • Oracle.

From this decade, that pharmaceutical testing industry holds many opportunities. And you examine its technological and commercial possibilities, staying ahead in knowledge.

Ways Pharmacovigilance and Related Developments: Industry and Market Analysis 2014-2024 helps.

In these four ways, that investigation gives you analysis found only in our work, helping you gain recognition for insight:

  • Revenues to 2024 at world level from that spending - assess prospects for investments, marketing, and sales
  • Forecasts to 2024 for 12 national markets in the Americas, Europe, and Asia - investigate developed and developing countries for commercial potentials
  • Outlooks for established, rising, and emerging product and service providers - explore results, capabilities, news, technologies, activities, and outlooks for success
  • Interviews with authorities in the pharmacovigilance industry - scan opinions to help you stay ahead.

Knowledge there found nowhere else, benefiting your searches, analyses, and planning.

Our new report gives competitive intelligence, showing where progress, demand, and money exist. Now you explore the pharmacovigilance industry's future through data exclusive to that study. So our analysis helps you avoid falling behind in information or missing opportunity. Also it lets you save time and effort. And now find how your choice can benefit your plans, decisions, and authority - increasing your chances of gaining advantages. Trying our new study on post-marketing testing and drug surveillance lets you explore those trends, opportunities, and sales predictions.

Stay ahead there - please get that report here now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Executive Summary

  • 1.1. Introduction to This New Study
  • 1.2. Chapter Contents - What You Find in That Work
  • 1.3. Research and Analysis Methods

2. Introduction to Pharmacovigilance

  • 2.1. Adverse Drug Reactions
    • 2.1.1. ADRs are Not Side Effects
    • 2.1.2. Terminology in the US and EU
  • 2.2. Never Events
  • 2.3. Safety Signals, What They Mean and How to Identify Them
  • 2.4. Pharmacovigilance, a Historical Perspective
    • 2.4.1. Thalidomide
    • 2.4.2. Eraldin
    • 2.4.3. Vioxx
    • 2.4.4. Avandia
  • 2.5. Drug Safety Monitoring in Clinical Trials
    • 2.5.1. Phase I Clinical Trials
    • 2.5.2. Phase II Clinical Trials
    • 2.5.3. Phase III Clinical Trials
      • 2.5.3.1. Limitations of Phase I-III Trials
  • 2.6. Phase IV - Post-Marketing Studies
  • 2.7. Pharmacovigilance in the Pharmaceutical Industry
  • 2.8. The Pharmacovigilance Practices of the Leading Pharmaceutical Companies
    • 2.8.1. Pfizer
    • 2.8.2. Johnson & Johnson
    • 2.8.3. GlaxoSmithKline
    • 2.8.4. Sanofi
    • 2.8.5. Novartis
    • 2.8.6. AstraZeneca
    • 2.8.7. Roche
    • 2.8.8. Abbott Laboratories
    • 2.8.9. Eli Lilly
    • 2.8.10. Bristol-Myers Squibb

3. Pharmacovigilance: World Market, 2014-2024

  • 3.1. The WHO Programme for International Drug Monitoring
    • 3.1.1. Data Collection at the Uppsala Monitoring Centre
    • 3.1.2. VigiBase - The Global Drug Safety Repository
  • 3.2. Pharmacovigilance in Research and Development: Forecast 2013-2024
  • 3.3. Global Pharmacovigilance Market Forecast 2013-2024
  • 3.4. Pharmacovigilance Market: Drivers and Restraints 2014-2024
    • 3.4.1. Volume of ADRs Set to Rise
    • 3.4.2. Reduced Pre-Market Safety Data - Focus Shifts to Post-Approval Monitoring
    • 3.4.3. New EU Regulations Will Demand a Revamp of Entire Pharmacovigilance Protocols
    • 3.4.4. Active Drug Safety Monitoring Set to Increase
    • 3.4.5. Lack of Harmonisation Leads to Cross Border Difficulties
    • 3.4.6. Transparency is Crucial in the Future of Pharmacovigilance
    • 3.4.7. Direct Consumer Reports Lack Quality to Detect Causal Safety Signals
    • 3.4.8. Merged Companies Spend Less on Pharmacovigilance

4. Leading National and Regional Markets, 2014-2024

  • 4.1. Regional Breakdown of the World Pharmacovigilance Market, 2013
  • 4.2. World Pharmacovigilance Market: Regional Forecast 2014-2024
    • 4.2.1. How Will Regional Market Shares Change to Between 2013 and 2024?
  • 4.3. The US Pharmacovigilance Market, 2014-2024
    • 4.3.1. Criticism of the FDA
    • 4.3.2. Periodic and Spontaneous Safety Reports
    • 4.3.3. ADR Metrics for the US Market, 2003-2012
    • 4.3.4. US Market Forecast, 2014-2024
  • 4.4. The European Pharmacovigilance Market, 2014-2024
    • 4.4.1. New EU Regulations Making the Biggest Impact for Twenty Years
    • 4.4.2. Quality at the Heart of Safety Monitoring
    • 4.4.3. Pharmacovigilance System Master File - Added Complexity in the Short Term
    • 4.4.4. ADR Reporting and Safety Signal Detection
    • 4.4.5. EU Market Forecast, 2014-2024
    • 4.4.6. ADR Metrics for the European Union, 2012
  • 4.5. The German Pharmacovigilance Market, 2014-2024
    • 4.5.1. German Market Forecast, 2014-2024
  • 4.6. The French Pharmacovigilance Market, 2014-2024
    • 4.6.1. French Market Forecast, 2014-2024
  • 4.7. The UK Pharmacovigilance Market, 2014-2024
    • 4.7.1. UK Market Forecast, 2014-2024
  • 4.8. The Italian Pharmacovigilance Market 2014-2024
    • 4.8.1. Italian Market Forecast, 2014-2024
  • 4.9. The Spanish Pharmacovigilance Market 2014-2024
    • 4.9.1. Spanish Market Forecast, 2014-2024
  • 4.10. Japanese Pharmacovigilance Market 2014-2024
    • 4.10.1. Early Stage Drug Monitoring
    • 4.10.2. Expedited and Periodic Safety Reports
    • 4.10.3. Japanese Market Forecast, 2014-2024
  • 4.11. Pharmacovigilance in the BRIC Nations, 2014-2024
  • 4.12. The Chinese Pharmacovigilance Market, 2014-2024
    • 4.12.1. ADR Metrics for the Chinese Market 2003-2012
    • 4.12.2. Chinese Market Forecast, 2014-2024
  • 4.13. The Brazilian Pharmacovigilance Market, 2014-2024
    • 4.13.1. Brazilian Market Forecast, 2014-2024
  • 4.14. The Russian Pharmacovigilance Market, 2014-2024
    • 4.14.1. Russian Market Forecast, 2014-2024
  • 4.15. The Indian Pharmacovigilance Market, 2014-2024
    • 4.15.1. ADR Metrics for Indian Market 2010-2013
    • 4.15.2. Indian Market Forecast 2014-2024
  • 4.16. The South Korean Pharmacovigilance Market, 2014-2024
    • 4.16.1. ADR Metrics for South Korea, 2003-2012
    • 4.16.2. South Korean Market Forecast, 2014-2024

5. Leading Pharmacovigilance Companies, 2014

  • 5.1. Business Process Outsourcing Firms
    • 5.1.1. Accenture - The Leading Business Process Outsourcing Firm
    • 5.1.2. Cognizant Technology Solutions
    • 5.1.3. Tata Consultancy Services
    • 5.1.4. Capgemini
    • 5.1.5. Tech Mahindra
    • 5.1.6. Infosys
    • 5.1.7. Wipro Limited
    • 5.1.8. HCL Technologies
    • 5.1.9. iGATE Corporation
  • 5.2. Contract Research Organisations (CROs)
    • 5.2.1. Quintiles Transnational
    • 5.2.2. Covance
    • 5.2.3. Parexel
    • 5.2.4. ICON
    • 5.2.5. inVentiv Health
    • 5.2.6. PRA International
    • 5.2.7. PharSafer
  • 5.3. Software Providers
    • 5.3.1. Oracle
    • 5.3.2. ArisGlobal
  • 5.4. Other Outsourcing Companies
    • 5.4.1. Drug Safety Alliance
    • 5.4.2. Foresight Group International
    • 5.4.3. TAKE Solutions
  • 5.5. Other Pharmacovigilance Service Providers

6. Qualitative Analysis of the Pharmacovigilance Market, 2014-2024

  • 6.1. SWOT Analysis of the Pharmacovigilance Market
  • 6.2. STEP Analysis of Factors Affect the Pharmacovigilance Market
  • 6.3. Social Forces
  • 6.4. Technological Forces
  • 6.5. Economic Forces
  • 6.6. Political Forces
  • 6.7. Increased Focus on Pharmacovigilance in the Emerging Markets
  • 6.8. Increasingly Complex Nature of Pharmaceutical Vigilance
  • 6.9. Harmonization of International Regulations Can Lead to Cost Reductions
  • 6.10. The Effect of the Internet and Social Media on ADR Reporting
  • 6.11. Collaboration between the FDA and EMA
  • 6.12. The Challenge of Obtaining High-Quality ADR Information
  • 6.13. Linking Pharmacovigilance to Genomics and Biomarkers
  • 6.14. Generics, Globalisation and Drug Safety

7. Research Interviews

  • 7.1. Interview with Nina Lahanis, Vice President of Marketing and Business Development, Drug Safety Alliance, USA
    • 7.1.1. What Activities Are Outsourced and Why?
    • 7.1.2. Mergers, Big Data, and New Regulations - The Challenges of Pharmacovigilance in the 21st Century
    • 7.1.3. Risk-Benefit Profiles and the Importance of Global Harmonisation
    • 7.1.4. Social Media and Electronic Health Records - Leading Trends in Pharmacovigilance
    • 7.1.5. The True Cost of Off-shoring
  • 7.2. Interview with Dr Angela van der Salm, Director of Pharmacovigilance, DADA Consultancy, Netherlands
    • 7.2.1. What Activities Are Outsourced and Why?
    • 7.2.2. The Challenges Posed by M&A Activity and New EU Regulations
    • 7.2.3. Heightened Awareness of Risk Management
    • 7.2.4. Transparency and Other Trends in Pharmacovigilance
    • 7.2.5. Actively Monitoring Drug Safety
  • 7.3. Interview with Mark Bartlett, Co-Founder and Managing Director, Geneix, UK
    • 7.3.1. Technological Impact on Pharmacovigilance
    • 7.3.2. Digital Healthcare Platforms and Pharmacovigilance
    • 7.3.3. Electronic Healthcare Records
    • 7.3.4. Role of Pharmacogenomics in Pharmacovigilance

8. Conclusions

  • 8.1. International Collaboration Will Increase
  • 8.2. Pharmacogenomics Will Become Important in Drug Approval and Safety Analysis
  • 8.3. Drug Safety Monitoring Will Become Active
  • 8.4. Social Media Will Become a Pharmacovigilance Tool

List of Tables

  • Table 2.1: Pharmacovigilance Terminology in the EU and US, 2014
  • Table 2.2: Sample Size Required to Detect ADRs Based on Incidence, 2014
  • Table 2.3: Number of Phase IV Clinical Trials by Registration Date, 2004-2014
  • Table 3.1: Full Members of the WHO Program for Drug Safety Monitoring, 2014
  • Table 3.2: Global Pharmaceutical R&D Spending Forecast: Global Spending on R&D ($bn), Annual Growth (%), CAGR (%), 2013-2024
  • Table 3.3: Global Pharmacovigilance Spending Forecast: Global Spending on Pharmacovigilance Operations ($bn), Proportion of R&D Spending (%), Annual Growth (%), CAGR (%), 2013-2024
  • Table 4.1: Spending on Pharmacovigilance in National and Regional Markets: Market Size ($bn), Market Share (%), 2013
  • Table 4.2: Forecast Spending on Pharmacovigilance in National and Regional Markets: Spending ($bn), Annual Growth (%), CAGR (%), 2013-2018
  • Table 4.3: Forecast Spending on Pharmacovigilance in National and Regional Markets: Spending ($bn), Annual Growth (%), CAGR (%), 2018-2024
  • Table 4.4: Forecast Spending on Pharmacovigilance in National and Regional Markets: Market Shares (%), 2013-2024
  • Table 4.5: Adverse Drug Reactions Entered into the FAERS Database: Expedited (000s), Medwatch (000s), Periodic (000s), Total Entered (000s), Annual Growth (%), 2003-2012
  • Table 4.6: Adverse Drug Reactions Entered into the FAERS Database by Country of Origin: Domestic (000s), Foreign (000s), Unknown (000s), Total Entered (000s), Annual Growth (%), 2003-2012
  • Table 4.7: Forecast Spending on Pharmacovigilance in the US: Spending ($bn), Annual Growth (%), CAGR (%), 2013-2024
  • Table 4.8: Forecast Spending on Pharmacovigilance in the European Union: National Market Sizes ($bn), Annual Growth (%), EU Market Shares (%), CAGRs (%), 2013-2018
  • Table 4.9: Forecast Spending on Pharmacovigilance in the European Union: National Market Sizes ($bn), Annual Growth (%), EU Market Shares (%), CAGRs (%), 2018-2024
  • Table 4.10: Individual Case Safety Reports Made to the Eudravigilance Database by Nation, 2012
  • Table 4.11: Forecast Spending on Pharmacovigilance in Germany: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
  • Table 4.12: Forecast Spending on Pharmacovigilance in France: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
  • Table 4.13: Forecast Spending on Pharmacovigilance in the UK: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
  • Table 4.14: Forecast Spending on Pharmacovigilance in Italy: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
  • Table 4.15: Forecast Spending on Pharmacovigilance in Spain: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
  • Table 4.16: Drug Re-examination Schedule in Japan, 2013
  • Table 4.17: ADRs Reported to Japanese Regulators: Domestic (000s), Foreign (000s), Healthcare Providers (000s), Annual Growth (%), 2008-2012
  • Table 4.18: Forecast Spending on Pharmacovigilance in Japan: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
  • Table 4.19: Forecast Spending on Pharmacovigilance in the BRIC Nations: Market Size ($bn), Annual Growth (%), Market Share (%), CAGR (%), 2013-2018
  • Table 4.20: Forecast Spending on Pharmacovigilance in the BRIC Nations: Market Size ($bn), Annual Growth (%), Market Share (%), CAGR (%), 2018-2024
  • Table 4.21: ADRs Reported to Chinese Regulators: ADRs Reported (000s), Annual Growth (%), 2003-2012
  • Table 4.22: Forecast Spending on Pharmacovigilance in China: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
  • Table 4.23: Forecast Spending on Pharmacovigilance in Brazil: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
  • Table 4.24: Forecast Spending on Pharmacovigilance in Russia: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
  • Table 4.25: ADRs Reported in India Regulators: ADRs Reported (000s), Annual Growth (%), 2010-2013
  • Table 4.26: Forecast Spending on Pharmacovigilance in India: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
  • Table 4.27: ADRs Reported to South Korean Regulators: ADRs Reported (000s), Annual Growth (%), 2003-2012
  • Table 4.28: Forecast Spending on Pharmacovigilance in South Korea: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
  • Table 5.1: Other Pharmacovigilance Service Providers, 2014
  • Table 7.1: Social, Technological, Economic, and Political Factors (STEP) Affecting Pharmacovigilance, 2014

List of Figures

  • Figure 2.1: Lifecycle of Adverse Events for Vioxx, 1999-2004
  • Figure 2.2: Lifecycle of Adverse Events for Avandia, 1999-2010
  • Figure 2.3: Number of Phase IV Clinical Trials by Registration Date, 2004-2014
  • Figure 3.1: Country of Origin of ICSRs on UMC VigiBase: National Percentage of Cumulative ISCR Total (%), Aug 2013
  • Figure 3.2: Per Capita ISCRs Submitted to VigiBase: Number ISCR Submitted Per Million Inhabitants Per Year, Yearly Average 2008-2013
  • Figure 3.3: Global Pharmaceutical R&D Spending Forecast ($bn), 2013-2024
  • Figure 3.4: Global Pharmacovigilance Spending Forecast: Global Spending on Pharmacovigilance Operations ($bn), Proportion of R&D Spending (%), 2013-2024
  • Figure 3.5: Pharmacovigilance Market: Drivers and Restraints, 2013-2024
  • Figure 4.1: Spending on Pharmacovigilance in National and Regional Markets: Market Share (%), 2013
  • Figure 4.2: Forecast Spending on Pharmacovigilance in National and Regional Markets: Spending ($bn), 2013-2024
  • Figure 4.3: Forecast Spending on Pharmacovigilance in National and Regional Markets: Market Share (%), 2018
  • Figure 4.4: Forecast Spending on Pharmacovigilance in National and Regional Markets: Market Share (%), 2024
  • Figure 4.5: Adverse Drug Reactions Entered into the FAERS Database: Expedited (000s), Medwatch (000s), Periodic (000s), 2003-2012
  • Figure 4.6: Adverse Drug Reactions Entered into the FAERS Database by Country of Origin: Domestic (000s), Foreign (000s), Unknown (000s), 2003-2012
  • Figure 4.7: Forecast Spending on Pharmacovigilance in the US: Market Size ($bn), 2013-2024
  • Figure 4.8: Forecast Spending on Pharmacovigilance in European Union (EU5): National Market Sizes ($bn), 2013-2024
  • Figure 4.9: Individual Case Safety Reports Made to the Eudravigilance Database by Nation, 2012
  • Figure 4.10: Forecast Spending on Pharmacovigilance in Germany: Market Size ($bn), 2013-2024
  • Figure 4.11: Forecast Spending on Pharmacovigilance in France: Market Size ($bn), 2013-2024
  • Figure 4.12: Forecast Spending on Pharmacovigilance in the UK: Market Size ($bn), 2013-2024
  • Figure 4.13: Forecast Spending on Pharmacovigilance in Italy: Market Size ($bn), 2013-2024
  • Figure 4.14: Forecast Spending on Pharmacovigilance in Spain: Market Size ($bn), 2013-2024
  • Figure 4.15: ADRs Reported to Japanese Regulators: Domestic (000s), Foreign (000s), Healthcare Providers (000s), 2008-2012
  • Figure 4.16: Forecast Spending on Pharmacovigilance in Japan: Market Size ($bn), 2013-2024
  • Figure 4.17: Forecast Spending on Pharmacovigilance in BRIC Nations: National Marker Sizes ($bn), 2013-2024
  • Figure 4.18: ADRs Reported to Chinese Regulators: ADRs Reported (000s), 2003-2012
  • Figure 4.19: Forecast Spending on Pharmacovigilance in China: Market Size ($bn), 2013-2024
  • Figure 4.20: Forecast Spending on Pharmacovigilance in Brazil: Market Size ($bn), 2013-2024
  • Figure 4.21: Forecast Spending on Pharmacovigilance in Russia: Market Size ($bn), 2013-2024
  • Figure 4.22: ADRs Reported in India: ADRs Reported (000s), 2010-2013
  • Figure 4.23: Forecast Spending on Pharmacovigilance in India: Market Size ($bn), 2013-2024
  • Figure 4.24: ADRs Reported to South Korean Regulators: ADRs Reported (000s), 2003-2012
  • Figure 4.25: Forecast Spending on Pharmacovigilance in South Korea: Market Size ($bn), 2013-2024
  • Figure 7.1: Strengths and Weaknesses in Pharmacovigilance, 2014
  • Figure 7.2: Opportunities and Threats in Pharmacovigilance, 2014

Companies Listed

  • Abbott Laboratories
  • Accenture
  • Accovion
  • Actavis
  • Agence française de sécurité sanitaire des produits de santé
  • Agencia Española de Medicamentos y Productos Sanitarios
  • Agenzia Italiana del Farmaco (AIFA)
  • Aprova
  • Aptiv Solutions
  • ARIS Global
  • AstraZeneca
  • Bayer
  • Brazilian Health Surveillance Agency (ANVISA)
  • Bristol-Myers Squibb
  • Capgemini
  • Center for Biologics Evaluation and Research
  • Center for Drug Evaluation and Research
  • Central Drugs Standard Control Organization
  • China Food and Drug Agency
  • China Food and Drug Agency (CFDA)
  • Chinese Ministry of Health
  • Cognizant Technology Solutions
  • Commission on Human Medicines
  • Committee for Medicinal Products for Human Use
  • Committee on the Safety of Medicine
  • Contergan Foundation
  • Covance
  • Crossoak Pharma
  • Crown Consultants
  • CSO Pharma Consulting
  • DADA Consultancy
  • Danish Medicines Agency
  • Dose Spot
  • Drug Safety Alliance
  • Dun & Bradstreet
  • Dutch Medicines Evaluation Board
  • Eli Lilly
  • Epidemico
  • European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • European Medicines Agency (EMA)
  • European Medicines Evaluation Agency (EMEA)
  • European Union (EU)
  • Facebook
  • Federal Association of Thalidomide Victims
  • Federal Centre for Monitoring Drug Safety
  • Federal Institute for Drugs and Medical Devices
  • Federal Service on Surveillance in Healthcare and Social Development (Roszdravnadzor, Russia)
  • First Databank
  • Food and Drug Administration (US FDA)
  • Foresight Group International
  • Forest Laboratories
  • GB Pharma
  • Geneix
  • GlaxoSmithKline (GSK)
  • Handle My Health
  • Harten Group
  • HCL Technologies
  • ICON
  • iGATE Corporation
  • Illumina
  • iMED Global
  • Imperial Chemical Industries
  • INC Research
  • Indian Pharmacopoeia Commission
  • Infosys
  • International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
  • inVentiv Health
  • IPM Safety Services
  • Japanese Pharmaceuticals and Medical Devices Agency
  • Johnson & Johnson
  • Kinapse
  • Korea Food and Drug Administration
  • Lindeq
  • Mahindra Satyam
  • Medicines and Healthcare Products Regulatory Agency (MHRA, UK)
  • MedImmune
  • Merck & Co.
  • Merck Serono
  • Ministero della Salute
  • Ministry of Food and Drug Safety (MFDS, Korea)
  • Ministry of Health, Labour and Welfare (MHLW, Japan)
  • National Agency for Safety of Medicine and Health Products
  • National Patient Safety Agency
  • NDA Group
  • Nhumi Technologies
  • Norwegian Medicines Agency
  • Novartis
  • November Research Group
  • Novo Nordisk
  • Optum
  • Oracle
  • Orbis Clinical
  • ParagonRX
  • Parexel
  • PatientsLikeMe
  • Patni Computer Systems
  • Paul Ehrlich Institute
  • Pfizer
  • Pharmaceutical and Medical Devices Agency (PMDA, Japan)
  • Pharmacovigilance Risk Assessment Committee
  • PharSafer
  • PPD
  • PRA International
  • Primevigilance
  • Quanticate
  • Quantum Solutions India
  • Quintiles Transnational
  • Ranbaxy
  • Roche
  • Sanofi
  • Sciformix
  • Serious Adverse Event Consortium (SAEC)
  • Servier
  • SGS Life Sciences
  • Shenyang Pharmaceutical University
  • State Food and Drug Agency
  • Sun Pharmaceuticals
  • Symogen
  • Synowledge
  • TAKE Solutions
  • Tata Consultancy Services
  • Tech Mahindra
  • Twitter
  • UDG Healthcare
  • uMotif
  • Unified Health System
  • United Biosource Company
  • Uppsala Monitoring Centre (UMC))
  • Warner Chilcott
  • Watson
  • Wipro Limited
  • Wockhardt
  • World Bank
  • World Health Organization (WHO)
  • Xendo
Back to Top